This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vivus' FDA Advisory Panel: Live Blog Recap

MOUNTAIN VIEW, Calif. ( TheStreet) -- Vivus (VVUS - Get Report) brings its weight-loss drug Qnexa in front of an advisory committee of the U.S. Food and Drug Administration today.

In a review posted to its Web site Tuesday, The FDA said Qnexa was effective in helping obese patients shed pounds, but the agency raised questions about the drug's safety.

The experts sitting on the FDA's Endocrinologic and Metabolic Drugs Advisory Committee will weigh data and testimony from Vivus and the FDA before voting on whether to recommend Qnexa for approval. The FDA is not required to follow the recommendation of its advisory panels, but most often it does.

Vivus is trying to become the first company in more than a decade to gain U.S. approval for a new weight-loss drug. Two other companies -- Arena Pharmaceuticals (ARNA - Get Report) and Orexigen Therapeutics (OREX - Get Report) -- are fast on its heels.

Vivus' Qnexa consists of two currently approved drugs: The generic weight-loss drug phentermine and topirimate, a drug used to treat epilepsy and migraine, marketed as Topomax by Johnson & Johnson (JNJ).

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARNA $1.45 -1.40%
OREX $1.60 -3.00%
VVUS $1.07 10.00%
AAPL $94.03 0.35%
FB $103.21 1.30%


Chart of I:DJI
DOW 15,893.71 +233.53 1.49%
S&P 500 1,847.89 +18.81 1.03%
NASDAQ 4,294.0220 +27.1850 0.64%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs